Highlights
1 patent
About
CBD-based Solutions for Treating Dyslipidemia
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.
CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction.
CannaLean Biotechs was established in partnership with Mor Research Applications.
Identity
| Name | Cannalean Biotechs |
|---|---|
| Slug | cannalean-biotechs |
| Type / kind | startup |
| Crunchbase ID | cannalean-biotechs |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OrKpLYIDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Bnei Brak |
| HQ address | Baruch Hirsch Street 14, Bnei Brak, Israel |
Web & social
| Website | https://www.cannaleanbio.com |
|---|---|
| https://www.linkedin.com/company/15809013 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical Cannabis
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business models
B2B
Tags
cannabismedical-cannabistreatmentsmetabolic-diseasepatientspharma-companiesvascularbiotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}